Regeneron (NASDAQ: REGN) reported Q1 EPS of $4.67, $0.35 better than the analyst estimate of $4.32. Revenue for the quarter came in at $1.51 billion versus the consensus estimate of $1.51 billion.

2018 Financial Guidance(3)

The Company's updated full year 2018 financial guidance consists of the following components:

Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses	$450 million–$485 million (previously $450 million–$500 million)
Non-GAAP unreimbursed R&D(2)(4)	$1.230 billion–$1.310 billion (previously $1.230 billion–$1.330 billion)
Non-GAAP SG&A(2)(4)	$1.325 billion–$1.395 billion (previously $1.350 billion–$1.450 billion)
Effective tax rate	15%–18% (previously 15%–19%)
Capital expenditures	$420 million–$480 million (previously $420 million–$500 million)

For earnings history and earnings-related data on Regeneron (REGN) click here.